GlaxoSmithKline plc (NYSE:GSK) announced a quarterly dividend on Thursday, November 1st, NASDAQ reports. Investors of record on Friday, November 16th will be given a dividend of 0.486 per share by the pharmaceutical company on Thursday, January 10th. This represents a $1.94 annualized dividend and a dividend yield of 4.71%. The ex-dividend date is Thursday, November 15th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.46.
GlaxoSmithKline has decreased its dividend by an average of 8.9% per year over the last three years. GlaxoSmithKline has a dividend payout ratio of 66.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect GlaxoSmithKline to earn $3.05 per share next year, which means the company should continue to be able to cover its $1.94 annual dividend with an expected future payout ratio of 63.6%.
NYSE GSK opened at $41.30 on Friday. The company has a debt-to-equity ratio of 6.66, a current ratio of 0.95 and a quick ratio of 0.63. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $42.36. The stock has a market capitalization of $101.21 billion, a P/E ratio of 14.34, a P/E/G ratio of 2.74 and a beta of 0.80.
GSK has been the subject of several research reports. TheStreet upgraded shares of GlaxoSmithKline from a “c” rating to a “b” rating in a research note on Monday, August 6th. Goldman Sachs Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 10th. Shore Capital upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a research note on Friday, July 27th. Argus increased their price target on shares of GlaxoSmithKline from $45.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, August 20th. Finally, Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Tuesday, September 25th. Eleven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $41.57.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: Earnings Reports
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.